JAK抑制剂在免疫介导性皮肤病患者中的心血管与静脉血栓栓塞风险:系统综述与Meta分析
结果显示JAK抑制剂与安慰剂/阳性对照相比,复合主要不良心血管事件(MACE)与全因死亡(OR 0.83,95%CI 0.44-1.57)及静脉血栓栓塞(VTE)(OR 0.52,95%CI 0.26-1.04)风险均无显著差异。
要点
- 在皮肤病适应症中,JAK抑制剂未显示增加MACE与全因死亡风险。
- JAK抑制剂与VTE风险无显著差异,但置信区间较宽。
- 仍需长期随访试验进一步明确JAK抑制剂在皮肤病中的安全性。
核心结论
- 在免疫介导性皮肤病患者中,JAK抑制剂与安慰剂/阳性对照相比未增加全因死亡、MACE和VTE风险。
研究设计与样本
- 系统综述与Meta分析,检索PubMed和ClinicalTrials.gov截至2023年4月1日。
- 纳入JAK抑制剂用于FDA已批准/待批准或欧盟/日本批准的皮肤病适应症、设安慰剂/阳性对照的3期随机临床试验。
- 排除无对照组研究、病例报告、观察性研究和综述。
- 采用随机效应模型和DerSimonian-Laird法计算比值比(OR)及95%CI,方案在PROSPERO前瞻性注册。
主要发现
- 复合MACE与全因死亡:JAK抑制剂 vs 安慰剂/阳性对照 OR 0.83(95%CI 0.44-1.57),无显著差异。
- VTE:JAK抑制剂 vs 安慰剂/阳性对照 OR 0.52(95%CI 0.26-1.04),无显著差异。
临床怎么用
- 该Meta分析结果不支持在皮肤病适应症中因MACE、VTE或死亡风险而对JAK抑制剂施加与类风湿关节炎相同的警示。
- 临床决策仍需结合患者个体心血管与血栓风险,并关注长期随访证据。
局限性
- 平均随访时间仅4.9个月,缺乏长期安全性数据。
- 部分适应症或人群的样本量可能有限,置信区间较宽。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Janus kinase (JAK) inhibitors are an effective treatment option for patients with certain skin-related conditions, such as atopic dermatitis, alopecia areata, and vitiligo, but there is a current US Food and Drug Administration (FDA) boxed warning label for oral and topical JAK inhibitors regarding increased risk of major adverse cardiovascular events (MACE), venous thromboembolism (VTE), serious infections, malignant neoplasm, and death. However, this boxed warning was precipitated by results of the Oral Rheumatoid Arthritis Trial (ORAL) Surveillance study, which only included patients with rheumatoid arthritis, and the same association may not be observed in dermatologic conditions. OBJECTIVE: To determine the risk of all-cause mortality, MACE, and VTE with JAK inhibitors in patients with dermatologic conditions. DATA SOURCES: PubMed and ClinicalTrials.gov were searched from database inception to April 1, 2023. STUDY SELECTION: This review included phase 3 randomized clinical trials with a placebo/active comparator group of JAK inhibitors used for a dermatologic indication with FDA approval or pending approval or with European Union or Japanese approval. Studies without a comparison group, case reports, observational studies, and review articles were excluded. DATA EXTRACTION AND SYNTHESIS: This study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. Adverse events using odds ratios (ORs) and 95% CIs were calculated using a random-effects model and the DerSimonian-Laird method. Studies were screened, data abstracted, and quality assessed by 2 independent authors. The protocol was prospectively registered with PROSPERO. MAIN OUTCOMES AND MEASURES: Primary outcomes were a composite of adjudicated MACE and all-cause mortality, and VTE. RESULTS: The analysis included 35 randomized clinical trials with 20 651 patients (mean [SD] age, 38.5 [10.1] years; male, 54%) and a mean (SD) follow-up time of 4.9 (2.68) months. Findings did not show a significant difference between JAK inhibitors and placebo/active comparator in composite MACE and all-cause mortality (OR, 0.83; 95% CI, 0.44-1.57) or VTE (OR, 0.52; 95% CI, 0.26-1.04). CONCLUSIONS AND RELEVANCE: In this systematic review and meta-analysis, use of JAK inhibitors was not associated with increased risk of all-cause mortality, MACE, and VTE compared to the placebo/active comparator groups. Additional trials with long-term follow-up are needed to better understand the safety risks of JAK inhibitors used for dermatologic indications.
引用
- Ingrassia JP, Maqsood MH, Gelfand JM, et al. Cardiovascular and Venous Thromboembolic Risk With JAK Inhibitors in Immune-Mediated Inflammatory Skin Diseases: A Systematic Review and Meta-Analysis. JAMA Dermatol. 2024. PMID: 37910098. doi:10.1001/jamadermatol.2023.4090
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。